Suppr超能文献

迟发性 Li-Fraumeni 综合征伴双侧乳腺癌及其他恶性肿瘤:病例报告及文献复习。

Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.

机构信息

Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Carl Gustav Carus, Fetscherstr, 74, 01307, Dresden, Germany.

出版信息

BMC Cancer. 2012 Jun 6;12:217. doi: 10.1186/1471-2407-12-217.

Abstract

BACKGROUND

Li-Fraumeni-Syndrome (LFS) is an autosomal-dominant, inherited tumour predisposition syndrome associated with heterozygous germline mutations in the TP53 gene. Patients with LFS are at a high risk to develop early-onset breast cancer and multiple malignancies, among which sarcomas are the most common. A high incidence of childhood tumours and close to 100% penetrance has been described. Knowledge of the genetic status of the TP53 gene in these patients is critical not only due to the increased risk of malignancies, but also because of the therapeutic implications, since a higher rate of radiation-induced secondary tumours in these patients has been observed.

CASE REPORT

We report a patient with LFS harbouring heterozygous, pathogenic TP53 germline mutation, who was affected by four synchronous malignancies at the age of 40: a myxofibrosarcoma of the right upper arm, bilateral breast cancer and a periadrenal liposarcoma. Radiological treatments and a surveillance program were adjusted according to recommendations for LFS patients.

CONCLUSION

Management of tumour treatment of patients with LFS is different to the general population because of their risk for secondary cancers in the radiation field. Screening procedures should take a possibly elevated risk for radiation induced cancer into account.

摘要

背景

李-佛美尼综合征(Li-Fraumeni-Syndrome,LFS)是一种常染色体显性遗传的肿瘤易感性综合征,与 TP53 基因的杂合胚系突变相关。LFS 患者罹患早发性乳腺癌和多种恶性肿瘤的风险较高,其中肉瘤最为常见。儿童肿瘤的发病率较高,近乎 100%的外显率已被描述。了解这些患者 TP53 基因的遗传状态不仅与恶性肿瘤的风险增加有关,还与治疗意义相关,因为这些患者中观察到放射性诱导的继发性肿瘤发生率更高。

病例报告

我们报告了一例 LFS 患者,其携带杂合性、致病性 TP53 胚系突变,在 40 岁时同时罹患四种恶性肿瘤:右上臂粘液纤维肉瘤、双侧乳腺癌和肾上腺周围脂肪肉瘤。根据 LFS 患者的建议,调整了放射治疗和监测方案。

结论

由于 LFS 患者在放射野中发生继发性癌症的风险较高,因此其肿瘤治疗的管理与一般人群不同。筛查程序应考虑可能升高的放射诱导癌症风险。

相似文献

2
A case of late-onset Li-Fraumeni-like syndrome with unilateral breast cancer.
Ann Lab Med. 2013 May;33(3):212-6. doi: 10.3343/alm.2013.33.3.212. Epub 2013 Apr 17.
3
TP53 germline mutation may affect response to anticancer treatments: analysis of an intensively treated Li-Fraumeni family.
Breast Cancer Res Treat. 2015 Jun;151(3):671-8. doi: 10.1007/s10549-015-3424-1. Epub 2015 May 16.
4
Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Int J Clin Oncol. 2021 Dec;26(12):2161-2178. doi: 10.1007/s10147-021-02011-w. Epub 2021 Oct 11.
5
Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.
Breast Cancer Res Treat. 2020 May;181(1):181-188. doi: 10.1007/s10549-020-05612-7. Epub 2020 Apr 3.
6
TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.
Fam Cancer. 2019 Apr;18(2):273-280. doi: 10.1007/s10689-018-00118-0.
10
Next generation sequencing is informing phenotype: a TP53 example.
Fam Cancer. 2018 Jan;17(1):123-128. doi: 10.1007/s10689-017-0002-1.

引用本文的文献

1
Baseline surveillance in Li Fraumeni syndrome using whole-body MRI: a systematic review and updated meta-analysis.
Eur Radiol. 2025 Feb;35(2):643-651. doi: 10.1007/s00330-024-10983-2. Epub 2024 Jul 29.
2
Li-Fraumeni syndrome in the setting of re-occurring malignancies after 27 years of remission: a case report.
Ann Med Surg (Lond). 2023 Apr 27;85(6):3012-3016. doi: 10.1097/MS9.0000000000000724. eCollection 2023 Jun.
4
Second Primary Malignancies in Patients with Well-differentiated/Dedifferentiated Liposarcoma.
Anticancer Res. 2018 Jun;38(6):3535-3542. doi: 10.21873/anticanres.12625.
5
Medical factors influencing decision making regarding radiation therapy for breast cancer.
Int J Womens Health. 2014 Nov 19;6:945-54. doi: 10.2147/IJWH.S71591. eCollection 2014.

本文引用的文献

1
Early onset HER2-positive breast cancer is associated with germline TP53 mutations.
Cancer. 2012 Feb 15;118(4):908-13. doi: 10.1002/cncr.26377. Epub 2011 Jul 14.
2
Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
Lancet Oncol. 2011 Jun;12(6):559-67. doi: 10.1016/S1470-2045(11)70119-X. Epub 2011 May 19.
6
2009 version of the Chompret criteria for Li Fraumeni syndrome.
J Clin Oncol. 2009 Sep 10;27(26):e108-9; author reply e110. doi: 10.1200/JCO.2009.22.7967. Epub 2009 Aug 3.
7
High frequency of de novo mutations in Li-Fraumeni syndrome.
J Med Genet. 2009 Oct;46(10):689-93. doi: 10.1136/jmg.2008.058958. Epub 2009 Jun 25.
8
Targeting p53 for enhanced radio- and chemo-sensitivity.
Apoptosis. 2009 Apr;14(4):597-606. doi: 10.1007/s10495-009-0330-1.
9
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
J Clin Oncol. 2009 Mar 10;27(8):1250-6. doi: 10.1200/JCO.2008.16.6959. Epub 2009 Feb 9.
10
Effect of recombinant adenovirus-p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma.
J Clin Oncol. 2009 Feb 10;27(5):799-804. doi: 10.1200/JCO.2008.18.9670. Epub 2008 Dec 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验